Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H28N6O |
| Molecular Weight | 440.5401 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)N1CCN(CC2=CN=C(O2)C3=CC(=CC4=C3C=NN4)C5=CC=CC6=C5C=CN6)CC1
InChI
InChIKey=MCIDWGZGWVSZMK-UHFFFAOYSA-N
InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)
| Molecular Formula | C26H28N6O |
| Molecular Weight | 440.5401 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
GSK-2269557 (nemiralisib), a PI3Kδ inhibitor, is in development as an anti-inflammatory drug for the treatment of inflammatory airways disease. Studies in moderate or severe stable COPD patients have shown an acceptable safety and tolerability profile when GSK-2269557 was administered via inhalation. Cough was the most commonly reported adverse event.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:51:26 UTC 2023
by
admin
on
Sat Dec 16 11:51:26 UTC 2023
|
| Record UNII |
OEP8JJ3OZR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000175715
Created by
admin on Sat Dec 16 11:51:26 UTC 2023 , Edited by admin on Sat Dec 16 11:51:26 UTC 2023
|
PRIMARY | |||
|
10314
Created by
admin on Sat Dec 16 11:51:26 UTC 2023 , Edited by admin on Sat Dec 16 11:51:26 UTC 2023
|
PRIMARY | |||
|
C174798
Created by
admin on Sat Dec 16 11:51:26 UTC 2023 , Edited by admin on Sat Dec 16 11:51:26 UTC 2023
|
PRIMARY | |||
|
1254036-71-9
Created by
admin on Sat Dec 16 11:51:26 UTC 2023 , Edited by admin on Sat Dec 16 11:51:26 UTC 2023
|
PRIMARY | |||
|
EF-40
Created by
admin on Sat Dec 16 11:51:26 UTC 2023 , Edited by admin on Sat Dec 16 11:51:26 UTC 2023
|
PRIMARY | |||
|
49784002
Created by
admin on Sat Dec 16 11:51:26 UTC 2023 , Edited by admin on Sat Dec 16 11:51:26 UTC 2023
|
PRIMARY | |||
|
OEP8JJ3OZR
Created by
admin on Sat Dec 16 11:51:26 UTC 2023 , Edited by admin on Sat Dec 16 11:51:26 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
>1000-fold selectivity to other isoforms
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
